Prednisone raw material characterization and formulation development

Detalhes bibliográficos
Autor(a) principal: Toehwé, Leonardo Henrique
Data de Publicação: 2017
Outros Autores: Prado, Livia Deris, Rocha, Helvécio Vinícius Antunes
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Pharmaceutical Sciences
Texto Completo: https://www.revistas.usp.br/bjps/article/view/142563
Resumo: Solid dosage forms for oral use, particularly tablets, are the most highly used dosage forms in therapy because they are easily administered, have high productivity and relatively low cost and provide a more stable drug to form a semi-solid net. Numerous parameters influence the quality of the final dosage form. In this study, the dissolution profile of 20-mg prednisone tablets bioequivalent to the reference product and three test formulations were evaluated using stability testing. During the study, prednisone tablets and the active pharmaceutical ingredient (API) prednisone from two different manufacturers were characterized with respect to their physical and physicochemical properties. The results showed that the dissolution profiles of the test batches and the reference product did not retain pharmaceutical equivalence throughout all the stability study. Notably, both samples of API prednisone were of the same crystal form, and any phase transition that occurred during the study could not be attributed to dissolution variation during stability.
id USP-31_8974c7f2918696d1071a42a5e4b8bcbd
oai_identifier_str oai:revistas.usp.br:article/142563
network_acronym_str USP-31
network_name_str Brazilian Journal of Pharmaceutical Sciences
repository_id_str
spelling Prednisone raw material characterization and formulation developmentPrednisone/tablets/dissolutionSolubilityFormulationStability Solid dosage forms for oral use, particularly tablets, are the most highly used dosage forms in therapy because they are easily administered, have high productivity and relatively low cost and provide a more stable drug to form a semi-solid net. Numerous parameters influence the quality of the final dosage form. In this study, the dissolution profile of 20-mg prednisone tablets bioequivalent to the reference product and three test formulations were evaluated using stability testing. During the study, prednisone tablets and the active pharmaceutical ingredient (API) prednisone from two different manufacturers were characterized with respect to their physical and physicochemical properties. The results showed that the dissolution profiles of the test batches and the reference product did not retain pharmaceutical equivalence throughout all the stability study. Notably, both samples of API prednisone were of the same crystal form, and any phase transition that occurred during the study could not be attributed to dissolution variation during stability.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2017-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/14256310.1590/s2175-97902017000400088Brazilian Journal of Pharmaceutical Sciences; Vol. 53 Núm. 4 (2017); e00088Brazilian Journal of Pharmaceutical Sciences; v. 53 n. 4 (2017); e00088Brazilian Journal of Pharmaceutical Sciences; Vol. 53 No. 4 (2017); e000882175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/142563/137596Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)info:eu-repo/semantics/openAccessToehwé, Leonardo HenriquePrado, Livia DerisRocha, Helvécio Vinícius Antunes2018-03-05T19:53:58Zoai:revistas.usp.br:article/142563Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2018-03-05T19:53:58Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Prednisone raw material characterization and formulation development
title Prednisone raw material characterization and formulation development
spellingShingle Prednisone raw material characterization and formulation development
Toehwé, Leonardo Henrique
Prednisone/tablets/dissolution
Solubility
Formulation
Stability
title_short Prednisone raw material characterization and formulation development
title_full Prednisone raw material characterization and formulation development
title_fullStr Prednisone raw material characterization and formulation development
title_full_unstemmed Prednisone raw material characterization and formulation development
title_sort Prednisone raw material characterization and formulation development
author Toehwé, Leonardo Henrique
author_facet Toehwé, Leonardo Henrique
Prado, Livia Deris
Rocha, Helvécio Vinícius Antunes
author_role author
author2 Prado, Livia Deris
Rocha, Helvécio Vinícius Antunes
author2_role author
author
dc.contributor.author.fl_str_mv Toehwé, Leonardo Henrique
Prado, Livia Deris
Rocha, Helvécio Vinícius Antunes
dc.subject.por.fl_str_mv Prednisone/tablets/dissolution
Solubility
Formulation
Stability
topic Prednisone/tablets/dissolution
Solubility
Formulation
Stability
description Solid dosage forms for oral use, particularly tablets, are the most highly used dosage forms in therapy because they are easily administered, have high productivity and relatively low cost and provide a more stable drug to form a semi-solid net. Numerous parameters influence the quality of the final dosage form. In this study, the dissolution profile of 20-mg prednisone tablets bioequivalent to the reference product and three test formulations were evaluated using stability testing. During the study, prednisone tablets and the active pharmaceutical ingredient (API) prednisone from two different manufacturers were characterized with respect to their physical and physicochemical properties. The results showed that the dissolution profiles of the test batches and the reference product did not retain pharmaceutical equivalence throughout all the stability study. Notably, both samples of API prednisone were of the same crystal form, and any phase transition that occurred during the study could not be attributed to dissolution variation during stability.
publishDate 2017
dc.date.none.fl_str_mv 2017-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/bjps/article/view/142563
10.1590/s2175-97902017000400088
url https://www.revistas.usp.br/bjps/article/view/142563
identifier_str_mv 10.1590/s2175-97902017000400088
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/bjps/article/view/142563/137596
dc.rights.driver.fl_str_mv Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
dc.source.none.fl_str_mv Brazilian Journal of Pharmaceutical Sciences; Vol. 53 Núm. 4 (2017); e00088
Brazilian Journal of Pharmaceutical Sciences; v. 53 n. 4 (2017); e00088
Brazilian Journal of Pharmaceutical Sciences; Vol. 53 No. 4 (2017); e00088
2175-9790
1984-8250
reponame:Brazilian Journal of Pharmaceutical Sciences
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Brazilian Journal of Pharmaceutical Sciences
collection Brazilian Journal of Pharmaceutical Sciences
repository.name.fl_str_mv Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)
repository.mail.fl_str_mv bjps@usp.br||elizabeth.igne@gmail.com
_version_ 1800222913311277056